Singapore Clinical Trial: A Phase 1, Open-Label, Pharmacokinetic Study of Lepodisiran Administered as a Single Subcutaneous Dose in the Abdomen, Thigh, or Upper Arm in Healthy Participants with High Lipoprotein(a)

Singapore, Oct. 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Pharmacokinetic Study of Lepodisiran Administered as a Single Subcutaneous Dose in the Abdomen, Thigh, or Upper Arm in Healthy Participants with High Lipoprotein(a)'. The following are the other relevant details related to the trial:

Therapeutic Area: Cardiology

Trial Centre(s): Lilly Centre for Pharmacology

Trial Status: NA

Principal Investigator(s): Dr Greg Li

Published by HT Digital Content Services with permission from Health Daily Digest....